Accentia Chronic Sinusitis Candidate Fails Phase III Clinical Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Disappointing trial data for intranasal lavage formulation sends Florida firm’s stock price tumbling by more than two-thirds.
You may also be interested in...
SinuNase Effective For Severe, Chronic Sinusitis After All
Results make a compelling argument to partnering candidates, Accentia tells “The Pink Sheet” DAILY.
SinuNase Effective For Severe, Chronic Sinusitis After All
Results make a compelling argument to partnering candidates, Accentia tells “The Pink Sheet” DAILY.
Biovest Ends Therapeutic Cancer Vaccine Trial Early On Positive DMC Signal
Firm seeks “accelerated or conditional” approval path from FDA.